Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke

2021221 citationsJournal Articlebronze Open Access

Authors

Jie Xu · Capital Medical University

Anxin Wang · Capital Medical University

Xia Meng · Capital Medical University

Gulbahram Yalkun · Capital Medical University

Anding Xu · First Affiliated Hospital of Jinan University

Zhiqiang Gao · Second Affiliated Hospital of Nanjing Medical University

Dawei Chen ·

Abstract

When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02430350.

Topics & Keywords

Acute Ischemic Stroke Management Neurological Disease Mechanisms and Treatments Neurological Disorders and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Stroke

Volume 52, Issue 3, pp. 772-780

DOI: 10.1161/strokeaha.120.031197

Field-Weighted Citation Impact: 19.44